{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:48:18Z","timestamp":1791287298294,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.4065\/mcp.2011.0309","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T18:01:02Z","timestamp":1317405662000},"page":"1009-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus"],"prefix":"10.4065","volume":"86","author":[{"given":"Raymund R.","family":"Razonable","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/mcp.2011.0309_bib1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.7326\/0003-4819-98-6-914","article-title":"Intravenous acyclovir for the treatment of primary genital herpes","volume":"98","author":"Corey","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(82)90658-4","article-title":"Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes","volume":"2","author":"Nilsen","year":"1982","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib3","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1001\/jama.1982.03320400044032","article-title":"Acyclovir treatment of herpes zoster infections: use in children undergoing bone marrow transplantation","volume":"247","author":"Serota","year":"1982","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib4","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib5","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1001\/jama.1984.03340400031020","article-title":"Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial","volume":"251","author":"Reichman","year":"1984","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/150.1.1","article-title":"A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo","volume":"150","author":"Luby","year":"1984","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archinte.168.11.1137","article-title":"The treatment of herpes simplex infections: an evidence-based review","volume":"168","author":"Cernik","year":"2008","journal-title":"Arch Intern Med"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0309_bib8","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1111\/j.1600-6143.2009.02900.x","article-title":"Herpes simplex virus infections in solid organ transplant recipients","volume":"9","author":"Zuckerman","year":"2009","journal-title":"Am J Transplant"},{"issue":"suppl A","key":"10.4065\/mcp.2011.0309_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/32.suppl_A.121","article-title":"Antivirals for the treatment of herpesvirus infections","volume":"32","author":"De Clercq","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2004-830372","article-title":"Relapse of herpes encephalitis after acyclovir therapy: report of two new cases and review of the literature","volume":"35","author":"Valencia","year":"2004","journal-title":"Neuropediatrics"},{"key":"10.4065\/mcp.2011.0309_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3476(05)81618-X","article-title":"Acyclovir treatment of varicella in otherwise healthy children","volume":"116","author":"Balfour","year":"1990","journal-title":"J Pediatr"},{"key":"10.4065\/mcp.2011.0309_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.7326\/0003-4819-117-5-358","article-title":"Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial","volume":"117","author":"Wallace","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/clinids\/22.2.341","article-title":"Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials","volume":"22","author":"Wood","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"suppl 10","key":"10.4065\/mcp.2011.0309_bib14","first-page":"66","article-title":"Other herpesviruses: HHV-6, HHV-7, HHV-8, HSV-1 and -2, VZV","volume":"4","year":"2004","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","article-title":"Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster","volume":"151","author":"Bean","year":"1985","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"10.4065\/mcp.2011.0309_bib17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/jac\/dkl067","article-title":"The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment","volume":"57","author":"Helld\u00e9n","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1345\/aph.17135","article-title":"Acyclovir- and ganciclovir-induced neurotoxicity","volume":"32","author":"Ernst","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-98-6-921","article-title":"Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation","volume":"98","author":"Wade","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1177\/106002809302701208","article-title":"Vesicular eruptions following acyclovir administration","volume":"27","author":"Buck","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(83)92618-1","article-title":"Megaloblastic haemopoiesis due to acyclovir","volume":"1","author":"Amos","year":"1983","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.4065\/mcp.2011.0309_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.4065\/mcp.2011.0309_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1086\/431585","article-title":"A retrospective, case-control study of acyclovir resistance in herpes simplex virus","volume":"41","author":"Malvy","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/092986708783955419","article-title":"New advances in anti-HSV chemotherapy","volume":"15","author":"Superti","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.4065\/mcp.2011.0309_bib26","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","author":"De Clercq","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.4065\/mcp.2011.0309_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","article-title":"Cidofovir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib28","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"10.4065\/mcp.2011.0309_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002239705","article-title":"Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis","volume":"43","author":"Wolf","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/mcp.2011.0309_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1345\/aph.17312","article-title":"Cidofovir in the treatment of cytomegaloviral disease","volume":"32","author":"Kendle","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1086\/314487","article-title":"In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome","volume":"178","author":"Cherrington","year":"1998","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib33","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/AAC.42.9.2240","article-title":"Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis","volume":"42","author":"Jabs","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib34","first-page":"1561","article-title":"Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients","volume":"3","author":"Snoeck","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.4065\/mcp.2011.0309_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-3062.2005.00099.x","article-title":"Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature","volume":"7","author":"Cha","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/135965350801300806","article-title":"Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature","volume":"13","author":"Lamoth","year":"2008","journal-title":"Antivir Ther"},{"key":"10.4065\/mcp.2011.0309_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0733-8635(02)00116-X","article-title":"Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox","volume":"21","author":"Toro","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.4065\/mcp.2011.0309_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/infdis\/170.3.570","article-title":"Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS","volume":"170","author":"Lalezari","year":"1994","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00006454-200111000-00016","article-title":"Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child","volume":"20","author":"Bryant","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.4065\/mcp.2011.0309_bib40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2133.2002.04747.x","article-title":"Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient","volume":"147","author":"Kopp","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.4065\/mcp.2011.0309_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/01.aids.0000216390.83351.87","article-title":"Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series","volume":"20","author":"Garvey","year":"2006","journal-title":"AIDS"},{"key":"10.4065\/mcp.2011.0309_bib42","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1097\/00002030-200209060-00012","article-title":"A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS","volume":"16","author":"Marra","year":"2002","journal-title":"AIDS"},{"key":"10.4065\/mcp.2011.0309_bib43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4065\/76.11.1171","article-title":"Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy","volume":"76","author":"Razonable","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2011.0309_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1345\/aph.10338","article-title":"Use of cidofovir in progressive multifocal leukoencephalopathy","volume":"35","author":"Segarra-Newnham","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s15010-006-5103-y","article-title":"Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis","volume":"35","author":"Viallard","year":"2007","journal-title":"Infection"},{"key":"10.4065\/mcp.2011.0309_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/599829","article-title":"Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study","volume":"49","author":"Cesaro","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2006.01.007","article-title":"Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection","volume":"55","author":"Kottke","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.4065\/mcp.2011.0309_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/dkm143","article-title":"Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir","volume":"60","author":"Kazory","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib49","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/bjo.83.10.1153","article-title":"Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis","volume":"83","author":"Ambati","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.4065\/mcp.2011.0309_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1345\/aph.17453","article-title":"Iritis associated with intravenous cidofovir","volume":"33","author":"Tseng","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199631010-00001","article-title":"The clinical pharmacokinetics of famciclovir","volume":"31","author":"Gill","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1098-0997(1998)6:1<38::AID-IDOG8>3.0.CO;2-3","article-title":"A review of famciclovir in the management of genital herpes","volume":"6","author":"Faro","year":"1998","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.4065\/mcp.2011.0309_bib53","first-page":"77","article-title":"Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications","volume":"80","author":"Chacko","year":"2007","journal-title":"Cutis"},{"key":"10.4065\/mcp.2011.0309_bib54","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1128\/AAC.38.10.2454","article-title":"Safety of famciclovir in patients with herpes zoster and genital herpes","volume":"38","author":"Saltzman","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1358\/dot.2001.37.4.620590","article-title":"Fomivirsen","volume":"37","author":"Grillone","year":"2001","journal-title":"Drugs Today (Barc)"},{"key":"10.4065\/mcp.2011.0309_bib56","first-page":"467","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","author":"Vitravene Study Group","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.4065\/mcp.2011.0309_bib57","first-page":"31","article-title":"Fomivirsen","volume":"29","author":"Highleyman","year":"1998","journal-title":"BETA"},{"key":"10.4065\/mcp.2011.0309_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib59","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1128\/AAC.40.12.2721","article-title":"Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS","volume":"40","author":"Balfour","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib60","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0309_bib61","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/infdis\/168.2.444","article-title":"A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS","volume":"168","author":"Jacobson","year":"1993","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib63","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0140-6736(90)92253-E","article-title":"Foscarnet and crystals in glomerular capillary lumens","volume":"336","author":"Beaufils","year":"1990","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib64","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/106002809402800908","article-title":"Neurologic sequelae associated with foscarnet therapy","volume":"28","author":"Lor","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1386-6532(99)00065-7","article-title":"Recent advances in the therapy and prevention of CMV infections","volume":"16","author":"Nichols","year":"2000","journal-title":"J Clin Virol"},{"key":"10.4065\/mcp.2011.0309_bib66","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0021-9258(17)43446-6","article-title":"Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate","volume":"259","author":"Frank","year":"1984","journal-title":"J Biol Chem"},{"key":"10.4065\/mcp.2011.0309_bib67","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/jlts.2002.34966","article-title":"The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation","volume":"8","author":"Razonable","year":"2002","journal-title":"Liver Transpl"},{"key":"10.4065\/mcp.2011.0309_bib68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/168.3.557","article-title":"A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS","volume":"168","author":"Spector","year":"1993","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib69","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM199509073331002","article-title":"Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS","volume":"333","author":"Drew","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib70","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [published correction appears in Lancet. 1998;351(9100):454]","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"10.4065\/mcp.2011.0309_bib72","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00705-003-0124-7","article-title":"Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials","volume":"148","author":"Sarisky","year":"2003","journal-title":"Arch Virol"},{"key":"10.4065\/mcp.2011.0309_bib73","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1128\/AAC.39.7.1599","article-title":"Activity of penciclovir against Epstein-Barr virus","volume":"39","author":"Bacon","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib74","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1001\/jama.1997.03540410052030","article-title":"Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial","volume":"277","author":"Spruance","year":"1997","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/106002809703100211","article-title":"Valacyclovir","volume":"31","author":"Acosta","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib76","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.1996.00440140169018","article-title":"A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis","volume":"156","author":"Spruance","year":"1996","journal-title":"Arch Intern Med"},{"issue":"suppl 4","key":"10.4065\/mcp.2011.0309_bib77","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1111\/j.1600-6143.2009.02901.x","article-title":"Varicella zoster virus (VZV) in solid organ transplant recipients","volume":"9","author":"Pergam","year":"2009","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib78","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.2.1.27","article-title":"Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts","volume":"2","author":"Razonable","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.4065\/mcp.2011.0309_bib80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib82","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/AAC.00085-09","article-title":"Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus","volume":"53","author":"Caldes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib83","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib85","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1086\/523589","article-title":"Use of valganciclovir for prevention and treatment of cytomegalovirus disease [editorial]","volume":"46","author":"Snydman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib87","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"10.4065\/mcp.2011.0309_bib88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/523590","article-title":"Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients","volume":"46","author":"Len","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib89","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.4065\/mcp.2011.0309_bib90","first-page":"CD002898","article-title":"Therapeutic interventions for herpes simplex virus epithelial keratitis","author":"Wilhelmus","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/mcp.2011.0309_bib91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"De Clercq","year":"2004","journal-title":"J Clin Virol"},{"issue":"11","key":"10.4065\/mcp.2011.0309_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13110","article-title":"Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation","volume":"13","author":"Tappenden","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.4065\/mcp.2011.0309_bib93","first-page":"304","article-title":"Amantadine and rimantadine for the prevention of influenza A","volume":"4","author":"Betts","year":"1989","journal-title":"Semin Respir Infect"},{"key":"10.4065\/mcp.2011.0309_bib94","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1099\/vir.2008.007260-0","article-title":"High prevalence of amantadine resistance among circulating European porcine influenza A viruses","volume":"90","author":"Krumbholz","year":"2009","journal-title":"J Gen Virol"},{"key":"10.4065\/mcp.2011.0309_bib95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2008.10.001","article-title":"Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada","volume":"44","author":"Higgins","year":"2009","journal-title":"J Clin Virol"},{"key":"10.4065\/mcp.2011.0309_bib96","first-page":"119","article-title":"Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine","volume":"176","author":"Hayden","year":"1992","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.4065\/mcp.2011.0309_bib97","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1128\/AAC.35.9.1741","article-title":"Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine","volume":"35","author":"Hayden","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0309_bib98","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib99","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/589748","article-title":"Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children","volume":"47","author":"Sugaya","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-151-7-200910060-00143","article-title":"Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza","volume":"151","author":"Khazeni","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib101","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib102","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa054512","article-title":"Oseltamivir resistance during treatment of influenza A (H5N1) infection","volume":"353","author":"de Jong","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib103","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/4371108a","article-title":"Avian flu: isolation of drug-resistant H5N1 virus","volume":"437","author":"Le","year":"2005","journal-title":"Nature"},{"key":"10.4065\/mcp.2011.0309_bib104","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib105","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib106","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00002018-199921040-00003","article-title":"Zanamivir: a review of clinical safety","volume":"21","author":"Freund","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"10.4065\/mcp.2011.0309_bib107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJMc0910893","article-title":"Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza [letter]","volume":"362","author":"Gaur","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib108","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(09)61528-2","article-title":"H1N1 pneumonitis treated with intravenous zanamivir","volume":"374","author":"Kidd","year":"2009","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib109","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2165\/00002018-200124150-00003","article-title":"Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications","volume":"24","author":"Gravenstein","year":"2001","journal-title":"Drug Saf"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0309_bib110","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin Liver Dis"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0309_bib111","first-page":"19","article-title":"Pegylation of interferon alfa: structural and pharmacokinetic properties","volume":"23","author":"Pedder","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.4065\/mcp.2011.0309_bib112","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib113","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199550050-00007","article-title":"Interferon-alpha-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis","volume":"50","author":"Haria","year":"1995","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.4065\/mcp.2011.0309_bib115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2893.2005.00599.x","article-title":"Treatment of chronic hepatitis B","volume":"12","author":"Marcellin","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.4065\/mcp.2011.0309_bib116","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib117","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated Interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib119","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of chronic hepatitis D with interferon alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib120","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.4065\/mcp.2011.0309_bib121","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","article-title":"Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel","volume":"19","author":"Soriano","year":"2005","journal-title":"AIDS"},{"key":"10.4065\/mcp.2011.0309_bib122","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.4065\/mcp.2011.0309_bib123","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"key":"10.4065\/mcp.2011.0309_bib124","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib125","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib126","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.4065\/mcp.2011.0309_bib127","first-page":"CD005445","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/mcp.2011.0309_bib128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.4065\/mcp.2011.0309_bib131","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.4065\/mcp.2011.0309_bib132","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib133","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib134","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"10.4065\/mcp.2011.0309_bib136","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1056\/NEJM198610233151704","article-title":"Interferon therapy for condylomata acuminata","volume":"315","author":"Eron","year":"1986","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib137","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003495-200060060-00007","article-title":"Current recommendations for the treatment of genital herpes","volume":"60","author":"Leung","year":"2000","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib138","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/13550289809114533","article-title":"Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study","volume":"4","author":"Huang","year":"1998","journal-title":"J Neurovirol"},{"key":"10.4065\/mcp.2011.0309_bib139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/13550280152537238","article-title":"The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS","volume":"7","author":"Geschwind","year":"2001","journal-title":"J Neurovirol"},{"key":"10.4065\/mcp.2011.0309_bib140","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"Psychiatric complications of long-term interferon alfa therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib141","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon19 alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.4065\/mcp.2011.0309_bib142","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/425746","article-title":"Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature","volume":"39","author":"Midturi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib143","first-page":"760","article-title":"Fluoxetine treatment of depression caused by interferon-alpha","volume":"88","author":"Levenson","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"10.4065\/mcp.2011.0309_bib144","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib145","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0140-6736(91)92132-L","article-title":"Liver failure due to recombinant alpha interferon","volume":"338","author":"Durand","year":"1991","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM198401053100107","article-title":"Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides","volume":"310","author":"Averbuch","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib147","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000065841","article-title":"Alopecia areata during interferon alpha-2b\/ribavirin therapy","volume":"205","author":"Agesta","year":"2002","journal-title":"Dermatology"},{"key":"10.4065\/mcp.2011.0309_bib148","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2125.2006.02704.x","article-title":"Pharmacokinetics of ribavirin in patients with hepatitis C virus","volume":"62","author":"Wade","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.4065\/mcp.2011.0309_bib149","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/AAC.34.3.489","article-title":"Hemodialysis clearance of intravenously administered ribavirin","volume":"34","author":"Kramer","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0309_bib150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jac\/dki405","article-title":"Treating HCV with ribavirin analogues and ribavirin-like molecules","volume":"57","author":"Gish","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib151","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1038\/ajg.2009.311","article-title":"Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus","volume":"104","author":"Gluud","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.4065\/mcp.2011.0309_bib152","first-page":"CD000181","article-title":"Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children","author":"Ventre","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4065\/mcp.2011.0309_bib153","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.healun.2008.10.008","article-title":"Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection","volume":"28","author":"Pelaez","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.4065\/mcp.2011.0309_bib154","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/378304","article-title":"Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada","volume":"37","author":"Knowles","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1592\/phco.27.4.494","article-title":"Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome","volume":"27","author":"Muller","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.4065\/mcp.2011.0309_bib156","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1542\/peds.99.2.261","article-title":"Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy","volume":"99","author":"McJunkin","year":"1997","journal-title":"Pediatrics"},{"key":"10.4065\/mcp.2011.0309_bib157","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ana.1062","article-title":"Treatment of acute Nipah encephalitis with ribavirin","volume":"49","author":"Chong","year":"2001","journal-title":"Ann Neurol"},{"key":"10.4065\/mcp.2011.0309_bib158","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever: effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib159","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib160","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(95)91323-8","article-title":"Crimean Congo-haemorrhagic fever treated with oral ribavirin","volume":"346","author":"Fisher-Hoch","year":"1995","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib161","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1086\/375058","article-title":"The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran","volume":"36","author":"Mardani","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib162","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/clind\/24.4.718","article-title":"Treatment of Bolivian hemorrhagic fever with intravenous ribavirin","volume":"24","author":"Kilgore","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib163","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199312023292321","article-title":"Hantavirus-associated acute respiratory failure","volume":"329","author":"Prochoda","year":"1993","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib164","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","article-title":"Adefovir dipivoxil: a review of its use in chronic hepatitis B","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib165","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1345\/aph.1D362","article-title":"Adefovir dipivoxil in the treatment of chronic hepatitis B","volume":"38","author":"Rivkin","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib166","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib167","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib168","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib169","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dkl551","article-title":"Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil","volume":"59","author":"Delaney","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0309_bib170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib171","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1592\/phco.26.12.1745","article-title":"Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection","volume":"26","author":"Sims","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.4065\/mcp.2011.0309_bib172","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","article-title":"Entecavir for the treatment of chronic hepatitis B virus infection","volume":"28","author":"Matthews","year":"2006","journal-title":"Clin Ther"},{"key":"10.4065\/mcp.2011.0309_bib173","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","article-title":"Entecavir: a review of its use in chronic hepatitis B","volume":"69","author":"Scott","year":"2009","journal-title":"Drugs"},{"key":"10.4065\/mcp.2011.0309_bib174","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of lamivudine","volume":"36","author":"Johnson","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib175","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","article-title":"A preliminary trial of lamivudine for chronic hepatitis B infection","volume":"333","author":"Dienstag","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib176","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib177","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib178","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(95)91829-9","article-title":"Hepatitis B reactivation after lamivudine","volume":"346","author":"Honkoop","year":"1995","journal-title":"Lancet"},{"key":"10.4065\/mcp.2011.0309_bib179","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0091270009333555","article-title":"Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment","volume":"49","author":"Zhou","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/mcp.2011.0309_bib180","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1345\/aph.1G027","article-title":"Telbivudine: a novel nucleoside analog for chronic hepatitis B","volume":"40","author":"Kim","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib181","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1742-1241.2006.01143.x","article-title":"Novel anti-hepatitis B agents: a focus on telbivudine","volume":"60","author":"Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.4065\/mcp.2011.0309_bib182","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib183","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial","volume":"147","author":"Chan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2011.0309_bib184","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.4065\/mcp.2011.0309_bib185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1345\/aph.1C388","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Grim","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.4065\/mcp.2011.0309_bib186","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib187","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hep.21307","article-title":"Tenofovir disoproxil fumarate: role in hepatitis B treatment","volume":"44","author":"Wong","year":"2006","journal-title":"Hepatology"},{"key":"10.4065\/mcp.2011.0309_bib188","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jhep.2007.12.006","article-title":"Potency of tenofovir in chronic hepatitis B: mono or combination therapy?","volume":"48","author":"Reijnders","year":"2008","journal-title":"J Hepatol"},{"key":"10.4065\/mcp.2011.0309_bib189","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14740338.6.2.155","article-title":"Tenofovir-induced kidney injury","volume":"6","author":"Gitman","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.4065\/mcp.2011.0309_bib190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.4065\/mcp.2011.0309_bib191","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00428-007-0418-3","article-title":"Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies","volume":"450","author":"Schmid","year":"2007","journal-title":"Virchows Arch"},{"key":"10.4065\/mcp.2011.0309_bib192","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1752-1947-2-94","article-title":"Acute renal failure in an AIDS patient on tenofovir: a case report","volume":"2","author":"Kapitsinou","year":"2008","journal-title":"J Med Case Reports"},{"key":"10.4065\/mcp.2011.0309_bib193","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.4065\/mcp.2011.0309_bib194","doi-asserted-by":"crossref","unstructured":"Foote BC, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C [Epub ahead of print August 9, 2011]. Ann Pharmacother. doi:10.1345\/aph.1P744.","DOI":"10.1345\/aph.1P744"},{"key":"10.4065\/mcp.2011.0309_bib195","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib196","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib197","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2007.03.116","article-title":"The hepatitis C virus life cycle as a target for new antiviral therapies","volume":"132","author":"Pawlotsky","year":"2007","journal-title":"Gastroenterology"},{"key":"10.4065\/mcp.2011.0309_bib198","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.4065\/mcp.2011.0309_bib199","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib200","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib201","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4065\/mcp.2011.0309_bib202","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611652439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:33:08Z","timestamp":1675902788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611652439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":202,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0025619611652439"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0309","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4065\/mcp.2011.0309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}